Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8785984 | Clinical Oncology | 2018 | 5 Pages |
Abstract
This small, prospective case series suggests that, in the short term, HDR brachytherapy is safe and well tolerated in IBD patients. Therefore, IBD should not automatically disqualify patients from, at least, HDR brachytherapy. The reason why these results differ from previous LDR studies possibly reflects the benefit of inverse planning, which more readily achieves rectal dose constraints in HDR brachytherapy.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
W. Mohammed, P. Hoskin, A. Henry, A. Gomez-Iturriaga, A. Robinson, A. Nikapota,